Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Abeona Therapeutics (ABEO) EBITDA: 2011-2025

Historic EBITDA for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -$5.1 million.

  • Abeona Therapeutics' EBITDA rose 83.10% to -$5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.4 million, marking a year-over-year increase of 216.09%. This contributed to the annual value of -$63.7 million for FY2024, which is 17.62% down from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' EBITDA is -$5.1 million, which was down 104.69% from $108.9 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' EBITDA peaked at $108.9 million during Q2 2025, and registered a low of -$46.7 million during Q4 2021.
  • In the last 3 years, Abeona Therapeutics' EBITDA had a median value of -$11.8 million in 2023 and averaged -$2.4 million.
  • As far as peak fluctuations go, Abeona Therapeutics' EBITDA slumped by 250.50% in 2024, and later soared by 1,359.97% in 2025.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' EBITDA stood at -$46.7 million in 2021, then soared by 84.57% to -$7.2 million in 2022, then crashed by 129.78% to -$16.6 million in 2023, then soared by 44.43% to -$9.2 million in 2024, then surged by 83.10% to -$5.1 million in 2025.
  • Its last three reported values are -$5.1 million in Q3 2025, $108.9 million for Q2 2025, and -$12.1 million during Q1 2025.